So the clinical development of Nimbaleukin began with Artistry one, which is the first in human trial of Nimbaleukin. Uh, was a phase 12 with expansions into multiple different cohorts. Part A, which is the dose escalation, looked as single agent, uh, and then Vleukin, as well as in combination with uh PDL1 inhibitor, uh pembrolizumab. Uh, once a dose was reached in both the monotherapy and the combination cohorts, there were expansion cohorts, uh, two expansion cohorts with monotherapy and advanced melanoma and advanced renal cell carcinoma, and then multiple, uh, expansion cohorts and combination therapy with pembrolizumab. Uh, these included patients that had previously been treated with PDL1 inhibitors, people that were PDL1 naive, uh, where there's no approval for PDL1 inhibitors, uh, as well as other specific, uh, disease populations, including non-small cell lung cancer, melanoma, head and neck, uh, squamous cell carcinomas, uh, to be looked at individually within the expansion cohorts. What was found in in expansion cohort C1, which is a cohort looking at patients with combination pembrolizumab andnvolleukin in disease states where PD1 therapy was not previously approved, and patients have not been treated with prior checkpoint inhibitors. Uh, there were 46 patients treated, uh, but what's interesting and relevant for me is that about 14 of those patients had, uh, advanced ovarian cancer, platinum resistant ovarian cancer. Um, most, all of those patients have been treated with uh 3 to 5 lines or more of prior therapy. And what we found is that 2 of those patients out of the 14 treated had complete responses and 2 more had partial responses, uh, which is very significant considering, uh, the, the, the general response rate we look at for single agent checkpoint inhibitors in the platinum resistant space is about 10%. And even for our best chemotherapies and patients that have had 345 lines of therapy, we're generally thinking 10 to 20% response rates and then the, and while a small patient population, 4 out of 14 is nearly 30% of patients having a meaningful response, especially with 2 of them having complete responses. And this is a very strong signal that this is uh a combination that we should look, uh look at more closely within the platinum resistant ovarian cancer space.
Presenter
